<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316520</url>
  </required_header>
  <id_info>
    <org_study_id>49RC19_0181</org_study_id>
    <nct_id>NCT04316520</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma</brief_title>
  <acronym>CETOREIN</acronym>
  <official_title>A Pilot Study Evaluating the Tolerability of a Ketogenic Diet With Vitamin Supplementation for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitaflo International, Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerance of one year of ketogenic diet&#xD;
      associated with vitamin supplementation in patients treated for a metastatic renal cell&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a pilot study evaluating the tolerance of a ketogenic diet associated&#xD;
      with a standard of care in patient with metastatic renal cell carcinoma.&#xD;
&#xD;
      The drugs involved in this study could be NIVOLUMAB + IPILIMUMAB, PEMBROLIZUMAB + AXITINIB,&#xD;
      SUNITINIB or PAZOPANIB.&#xD;
&#xD;
      Cancer cells are known to have an increased glycolytic activity that allows them to product&#xD;
      energy from anaerobic degradation of glucose. A ketogenic diet places the body in ketosis&#xD;
      state. It forces the body to burn fat instead of glucose. Fat metabolism occurs via the&#xD;
      mitochondrial oxidative phosphorylation. By reducing sugar intake and regulating energy&#xD;
      metabolism, the ketogenic diet could contribute to limit tumor progression.&#xD;
&#xD;
      This diet will be introduced during one year, patient will be monitored closely with&#xD;
      biological tests and radiological assessments every three month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of one year of ketogenic diet 2:1</measure>
    <time_frame>1 year</time_frame>
    <description>Frequency of adverse events evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance of ketogenic diet</measure>
    <time_frame>1 year</time_frame>
    <description>Pourcentage of compliant patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival according to RECIST 1.1 at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Ketogenic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketogenic diet + standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketogenic diet</intervention_name>
    <description>Ketogenic diet 2:1</description>
    <arm_group_label>Ketogenic diet</arm_group_label>
    <other_name>First line treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject with histologically-confirmed renal cell carcinoma&#xD;
&#xD;
          2. At least one CT-verified metastasis ≥ 10 mm, not previously irradiated&#xD;
&#xD;
          3. First line treatment : PAZOPANIB, SUNITINIB, PEMBROLIZUMAB/AXITINIB or&#xD;
             NIVOLUMAB/IPILIMUMAB&#xD;
&#xD;
          4. No prior treatment for the metastatic renal cell carcinoma&#xD;
&#xD;
          5. Men and women, aged ≥ 18 years&#xD;
&#xD;
          6. OMS ≤ 1&#xD;
&#xD;
          7. Screening laboratory values must meet the following criteria and should be obtained&#xD;
             prior to commencement of treatment:&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g/dL, neutrophils ≥ 1000 /mm3, platelets ≥ 100 000 /mm3,&#xD;
                  leukocytes ≥ 2000 /mm3&#xD;
&#xD;
               2. Total bilirubin ≤ 1,5 ULN, ASAT and ALAT ≤ 3 x ULN&#xD;
&#xD;
               3. Creatinine clearance ≥ 30 mL/min, verified proteinuria above or equal to 1g/24&#xD;
                  hours measured from 24 hours of urine if the urinary protein&#xD;
&#xD;
               4. Corrected calcium ≤ ULN&#xD;
&#xD;
          8. Patient must have signed and dated informed consent&#xD;
&#xD;
          9. Patient must have an internet connection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindication to a ketogenic diet : primary carnitine deficiency, fatty acid&#xD;
             beta-oxidation and cytogenesis deficiencies, pyruvate carboxylate deficiency,&#xD;
             porphyria&#xD;
&#xD;
          2. Swallowing disorder&#xD;
&#xD;
          3. Important surgical procedure within the 4 weeks before treatment&#xD;
&#xD;
          4. Prior radiotherapy must have been completed at least 2 weeks prior to treatment&#xD;
&#xD;
          5. Pregnant women or breastfeeding&#xD;
&#xD;
          6. Subjects with previous malignancies (except non-melanoma skin cancer and the following&#xD;
             endometrial in situ cancers) are excluded unless a complete remission was achieved at&#xD;
             least 3 years prior to study entry and no additional therapy is required during the&#xD;
             study period&#xD;
&#xD;
          7. Subjects with brain metastases, uncontrolled compression of the spinal cord,&#xD;
             carcinomatous meningitis, signs of cerebral or leptomeningeal involvement&#xD;
&#xD;
          8. Uncontrolled blood pressure (SBP &gt;150 mmH et DBP &gt;100 mmHg)&#xD;
&#xD;
          9. Any serious or uncontrolled medical disorder during the last 6 months : hepatic&#xD;
             insufficiency, renal insufficiency, respiratory insufficiency&#xD;
&#xD;
         10. Patients with any severe medical conditions within 6 month prior to inclusion such as&#xD;
             : myocardial infarction, severe/instable angina pectoris, coronary artery bypass&#xD;
             surgery, NYHA III or IV congestive heart failure, stroke or transient ischemic attack&#xD;
&#xD;
         11. Patients with sere medical conditions within 3 month prior to inclusion such as :&#xD;
             grade 3 or grade 4 gastrointestinal bleeding, peptic ulcer treatment resistant,&#xD;
             esophagitis or ulcerated gastritis, infectious or inflammatory bowel disease,&#xD;
             diverticulitis, thrombosis, pulmonary embolism or other uncontrolled thromboembolic&#xD;
             event, unhealed bone fractures&#xD;
&#xD;
         12. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
         13. Malabsorption syndrome&#xD;
&#xD;
         14. Uncontrolled infection&#xD;
&#xD;
         15. QT/QTc interval &gt; 450 msec for men and &gt; 470 msec for women&#xD;
&#xD;
         16. Concomitant treatments : strong inducers of CYP3A4 (DEXAMETHASONE, PHENYTOINE,&#xD;
             CARBAMAZEPINE, RIFAMPICINE, RIFABUTINE, RIFAPENTINE, PHENOBARBITAL, and ST. JOHN'S&#xD;
             WORT)&#xD;
&#xD;
         17. Social, psychological or medical condition that may interfere with participation in&#xD;
             the study or its evaluation&#xD;
&#xD;
         18. Patient deprived of liberty by judicial or administrative decision&#xD;
&#xD;
         19. Patient with psychiatric treatment under duress&#xD;
&#xD;
         20. Patient subject to legal protection measures&#xD;
&#xD;
         21. Patient unable to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre BIGOT, MD PhD</last_name>
    <phone>+33241356494</phone>
    <email>pibigot@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BIGOT</last_name>
      <email>pierre.bigot@chu-angers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic renal cancer</keyword>
  <keyword>ketogenic diet</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>first line treatment</keyword>
  <keyword>targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

